Immunizing a human VH1-2/Vκ1-33-rearranging mouse model with SARS-CoV-2 spike protein immunogens elicited several VH1-2/Vκ1-33-based neutralizing antibodies that bound receptor-binding-domain in a different mode from each other and from those of many prior human patient-derived VH1-2-based neutralizing antibodies.
[Science Immunology]